Vitamin C (intravenous) and anticancer treatment: state of evidence and perspectives

Initial note: this article has been previously published and updated according to scientific and divulgative criteria. The text summarizes available evidence and does not replace medical advice. Purpose: to transparently inform about research related to the use of high-dose vitamin C for oncology patients.

In brief

• Intravenous administration of vitamin C can achieve plasma concentrations much higher than those attainable orally.
• Preclinical studies show that pharmacological concentrations can generate hydrogen peroxide in the extracellular environment, with selective damage to tumor cells in experimental models.
• Small phase I/II clinical studies indicate tolerability and possible signs of efficacy in combination with chemotherapy, but evidence remains limited and variable.
• A recent randomized trial reported improved outcomes in a selected population with advanced pancreatic cancer; larger-scale confirmations and patient selection criteria are needed.
• No generalized clinical recommendations exist: every approach should be considered within controlled studies or in collaboration with the oncology team.

Abstract: what does science say?

What is meant by "pharmacological vitamin C"

"Pharmacological vitamin C" refers to doses of ascorbic acid administered intravenously that achieve plasma concentrations (millimolar) much higher than those obtainable with oral intake. At these levels, the molecule can behave differently from its nutritional function: in addition to the known antioxidant activity at low concentrations, under pharmacological conditions it can act as a local pro-oxidant, promoting the formation of oxidizing species in the extracellular environment.

What the available evidence broadly shows

Experimental data in cells and animal models indicate that intravenously administered vitamin C can increase the sensitivity of some tumor cell lines to chemotherapy and radiotherapy and can induce cell death through mechanisms related to extracellular oxidative stress. Small phase I/II clinical studies have evaluated safety and pharmacokinetics and reported tolerability; some report signs of benefit when vitamin C is used with chemotherapy in selected tumors. Recently, a randomized trial in patients with metastatic pancreatic carcinoma was published, reporting an improvement in median survival in the group treated with chemotherapy plus intravenous vitamin C, but the results require independent and broader confirmation.

Interpretive limitations

Current evidence does not allow for definitive causal statements for most tumors. Variability between studies (doses, administration schedule, tumor types, patient selection criteria) prevents generalizations. It is essential to distinguish between biological plausibility and consolidated clinical proof: the former is robust in experimental models; the latter remains incomplete and subject to bias until large, randomized, and replicated trials are available.

What it means in practice

Available scientific information suggests that the use of vitamin C at pharmacological concentrations differs substantially from common dietary or supplemental use. The intravenous route is a necessary condition to achieve millimolar plasma concentrations that are potentially biologically active [1]. In in vitro and in vivo models, high concentrations act as a source of hydrogen peroxide in the extracellular environment, a mechanism that can preferentially damage tumor cells compared to normal cells [2][3]. Preclinical studies have also shown synergies between ascorbate at pharmacological doses and various chemotherapeutic agents, offering a rationale for combined experiments [4].

Safety and tolerability

Phase I trials and small clinical studies have generally shown good tolerability of high-dose infusions, with rare severe adverse effects when contraindications are respected (e.g., undiagnosed G6PD deficiency or impaired renal function) [5][6]. In studies combining vitamin C with chemotherapy, no consistent increases in overall toxicity were observed, but clinical and laboratory surveillance remains mandatory during administration [5][7].

Which patients and in which contexts?

Currently, the experimental use of intravenous vitamin C should be limited to clinical protocols or pathways agreed upon with the oncology team. Some pilot and phase I studies have involved patients with refractory advanced tumors, while others have evaluated combinations with standard regimens (e.g., gemcitabine ± erlotinib or carboplatin/paclitaxel) with the primary objective of safety but also a signal of efficacy [5][7][4]. A recent randomized trial in metastatic pancreatic carcinoma reported favorable clinical results in the arm with added vitamin C to chemotherapy, but this is a single study that requires replication and in-depth analysis before being translated into guidelines [8].

Key points to remember

1) Route of administration matters: intravenous administration allows for plasma concentrations that oral intake cannot achieve, and this is central to the hypothesized mechanism of action.

2) Plausible mechanism: at pharmacological concentrations, ascorbic acid can promote the local production of reactive oxygen species (hydrogen peroxide) capable of damaging tumor cells in experimental models.

3) Mixed evidence: preclinical evidence is consistent and promising; clinical evidence is currently based on small, not always randomized studies, and on some phase I/II trials demonstrating tolerability and signs of efficacy in combination with chemotherapy.

4) Recent progress: a randomized trial in metastatic pancreatic carcinoma reported improved outcomes with the addition of vitamin C to chemotherapy; however, independent confirmations and more extensive studies are needed.

5) Not a standalone therapy: currently, intravenous vitamin C is not approved as a first-line anti-cancer treatment; its use should be limited to clinical protocols or pathways agreed upon with the treating oncologist.

Limitations of evidence

Distinguishing between study types: many results come from preclinical studies, animal models, and laboratory studies that provide biological plausibility but not proof of efficacy in humans. Observational studies and clinical series offer useful information on tolerability and possible secondary effects, but are not sufficient to demonstrate a causal effect on oncological outcomes. Robust clinical conclusions require randomized, controlled, and replicated trials on adequate samples.

Recurring methodological limitations: small sample sizes, heterogeneity of studied populations, lack of standardization of doses and administration schedules, different endpoints between studies (quality of life, overall survival, radiological response), and often limited follow-up. These factors increase the risk of overestimating initial results.

Context variability: the potential effect of vitamin C can strongly depend on the type of tumor, disease stage, concomitant therapies, the patient's metabolic status, and the tumor's ability to metabolize oxidizing species (e.g., levels of catalase and intracellular antioxidant systems). Such variables make it difficult to generalize data and require personalized approaches in clinical research.

Need for caution: until large, randomized, and independent clinical studies confirming preliminary results are available, intravenous vitamin C should be considered an experimental strategy with a biological rationale but not yet validated as a standard anti-cancer therapy.

Editorial conclusion

Research into the therapeutic effects of intravenously administered vitamin C has regained solid scientific interest over the past fifteen years, thanks to a plausible mechanistic basis and consistent preclinical data. Small phase I/II clinical studies have shown that pharmacological doses are achievable and generally well tolerated. Clinical evidence of efficacy, however, remains fragmented: promising signals must be confirmed with well-designed studies, with clear inclusion/exclusion criteria and relevant clinical endpoints. In the meantime, the use of intravenous vitamin C in oncology should occur through rigorous clinical trials or in centers that can ensure adequate monitoring and multi-disciplinary collaboration. The scientific community and public bodies have a key role in funding and coordinating independent research that can clarify the utility, limitations, and safety of this strategy.

Editorial note

This text is an update of a pre-existing article, revised according to criteria of scientific accuracy and divulgative clarity. The cited information is based on verified primary studies and peer-reviewed reviews and on the DOIs indicated in the following section. The information provided here is for informational purposes only and does not replace professional medical advice.

SCIENTIFIC RESEARCH

1. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140(7):533-537. https://doi.org/10.7326/0003-4819-140-7-200404060-00010
2. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005;102(38):13604-13609. https://doi.org/10.1073/pnas.0506390102
3. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A. 2007;104(21):8749-8754. https://doi.org/10.1073/pnas.0702854104
4. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18. https://doi.org/10.1126/scitranslmed.3007154
5. Monti DA, Mitchell E, Bazzan AJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. https://doi.org/10.1371/journal.pone.0029794
6. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19(11):1969-1974. https://doi.org/10.1093/annonc/mdn377
7. Welsh JL, Wagner BA, van’t Erve TJ, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node‑positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013;71(3):765-775. https://doi.org/10.1007/s00280-013-2070-8
8. Bodeker KL, Smith BJ, Berg DJ, et al. A randomized trial of pharmacological ascorbate, gemcitabine, and nab‑paclitaxel for metastatic pancreatic cancer. Redox Biol. 2024;77:103375. https://doi.org/10.1016/j.redox.2024.103375
9. Böttger F, Vallés‑Martí A, Cahn L, Jimenez CR. High‑dose intravenous vitamin C, a promising multi‑targeting agent in the treatment of cancer. J Exp Clin Cancer Res. 2021;40:343. https://doi.org/10.1186/s13046-021-02134-y

Note: all references reported have been verified via active DOI and correspond to the cited bibliographic data.